Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in a fireside chat at the Stifel Healthcare Conference on November 16, 2022, at 4:10 p.m. ET. The live webcast will be accessible under the Investors tab on Acumen's website, where it will be archived for 14 days.

Acumen focuses on developing novel therapeutics for Alzheimer’s disease, targeting toxic soluble AβOs with its investigational product candidate, ACU193, currently in a Phase 1 clinical trial for early Alzheimer’s patients.

News Market Reaction – ABOS

+4.35%

+4.35% Session move

In the trading session that priced this news, ABOS gained 4.35%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022 at 4:10 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals participate in the Stifel Healthcare Conference?

Acumen Pharmaceuticals will participate in the Stifel Healthcare Conference on November 16, 2022, at 4:10 p.m. ET.

How can I watch the Acumen Pharmaceuticals webcast at the Stifel Healthcare Conference?

The live webcast of the Acumen Pharmaceuticals discussion can be accessed under the Investors tab on their website.

What is the focus of Acumen Pharmaceuticals?

Acumen Pharmaceuticals is focused on developing novel targeted therapeutics for Alzheimer’s disease.

What is the investigational product candidate being developed by Acumen?

Acumen is developing ACU193, a humanized monoclonal antibody targeting toxic soluble AβOs.

What clinical trial is Acumen Pharmaceuticals currently conducting?

Acumen Pharmaceuticals is conducting the INTERCEPT-AD Phase 1 clinical trial involving early Alzheimer’s disease patients.